The CD2AP gene is located on chromosome 6 at p12.3 and encodes the CD2 associated protein. CD2AP acts as a scaffolding protein that interacts with the cytoplasmic domain of nephrin in complex with podocin. Provides structure/regulation to the foot process of podocytes and the slit diaphragm (PMID: 11733557). In the kidney, CD2AP is primarily expressed in glomerular podocytes, and its absence results in improper formation of the slit diaphragm (PMID: 10514378) and the protein filtration barrier of the kidney (PMID: 16889564).
Multiple disease entities have been reported in association with this gene. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, there was evidence of differences in their inheritance pattern. Therefore, the following disease entities have been split into multiple disease entities: autosomal dominant focal segmental glomerulosclerosis (FSGS) (OMIM:607832) and autosomal recessive FSGS (OMIM:607832). Autosomal dominant FSGS has been curated separately.
CD2AP was first reported in relation to autosomal recessive FSGS in 2007 (Löwik et al., PMID: 17713465). FSGS is a pathologic entity associated clinically with proteinuria, nephrotic syndrome (NPHS), and progressive loss of renal function. It is a common cause of end-stage renal disease (ESRD) (PMID: 16932363). The mechanism of pathogenicity is known to be loss of function.
Four variants (nonsense and frameshift) have been reported in four probands in four publications (PMIDs: 17713465, 30348286, 30612599, 36964972) included in this curation. A total of 7.1/12 pts. for genetic evidence was reached considering case-level data.
This gene-disease relationship is also supported by functional studies, expression studies, and animal models. One mouse model with homozygous knock-in of c.592_593insTCAC (p.Ser198IlefsTer3), which is also observed in a patient with FSGS, phenocopied FSGS (PMIDs: 30612599). Additionally, CD2AP expression is observed in the glomerular basement membrane and is required for proper formation of the slit diaphragm and the protein filtration barrier of the kidney (PMID: 10514378, 10997929, 16889564). A total of 5/6 pts. for experimental evidence was reached.
In summary, there is definitive evidence supporting the relationship between CD2AP and autosomal recessive focal segmental glomerulosclerosis. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.
This classification was approved by the ClinGen Glomerulopathy GCEP on the meeting date April 8, 2024 (SOP Version 10).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.